Gan & Lee Pharmaceuticals synthesizes new CK1α molecular glue degraders

July 20, 2026

Gan & Lee Pharmaceuticals Co. Ltd. has divulged new molecular glue degraders comprising cereblon (CRBN)-binding agents and casein kinase 1 isoform α (CK1α, CSNK1A1) degradation moieties potentially useful for the treatment of cancer.

BioWorld Science Cancer Degradation inducer Patents

Today's news in brief

BioWorld

BioWorld briefs for July 24, 2026.

4D Nucleome opens new wave of gene regulation research, discovery

BioWorld

After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...

Other news to note for July 22, 2026

BioWorld

Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Akari, Ashlins, Azurity, Eli Lilly, Engitix, Forge Biologics,...

Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s

BioWorld Science

Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...

GSK’s newly acquired Jideytro wins FDA nod in NSCLC

BioWorld

About a week after closing its $10.6 billion acquisition of Nuvalent Inc., GSK plc has reaped the first reward, announcing U.S. FDA approval of zidesamtinib in...